By highlighting the safety advantages of its Microcyn technology, Sonoma Pharmaceuticals could see a positive short-term impact on its stock price. This is due to the potential for increased market demand for safer dermatological products, especially in light of concerns surrounding benzoyl peroxide. The company's emphasis on the safety and efficacy of its products could enhance its reputation and market share in the dermatological sector.